Immunogenicity and other problems associated with the use of biopharmaceuticals
Open Access
- 10 May 2011
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 2 (3), 113-128
- https://doi.org/10.1177/2042098611406318
Abstract
Biopharmaceuticals are used widely for the treatment of cancer, chronic viral hepatitis, inflammatory, and autoimmune diseases. Biopharmaceuticals such as interferons are well tolerated for the most part with the most common adverse events observed being ‘flu-like’ symptoms that resolve rapidly after initial treatment. Prolonged treatment is associated, however, with more serious adverse events including leucopenia, thrombocytopenia, and neuropsychiatric effects, which may necessitate dose reduction or even cessation of treatment in some patients. Recombinant growth factors, such as erythropoietin (EPO), granulocyte colony-stimulating factor, or granulocyte macrophage colony-stimulating factor, are for the most part well tolerated, although severe complications have been reported in patients with cancer or chronic kidney disease treated with EPO. Similarly, treatment of patients with cancer with high doses of interleukin-2 is associated with significant toxicity. Treatment of chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn’s disease, with antitumor necrosis factor-alpha monoclonal antibodies is associated with an increased risk of granulomatous infections and, in particular, tuberculosis. The monoclonal antibody, natalizumab, that targets alpha4 integrins is effective in the treatment of multiple sclerosis but is associated with the activation of JC virus and development of progressive multifocal leukoencephalopathy. Repeated administration of recombinant proteins can cause a break in immune tolerance in some patients resulting in the production of a polyclonal antibody response that can adversely affect pharmacokinetics and clinical response. In addition, neutralizing antibodies that cross react with nonredundant essential proteins such as EPO can cause severe autoimmune reactions.Keywords
This publication has 115 references indexed in Scilit:
- A loss‐of‐function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patientsEMBO Molecular Medicine, 2011
- Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic MicePharmaceutical Research, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals Of The Rheumatic Diseases, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- The Neutralization of Interferons by Antibody III. The Constant Antibody Bioassay, A Highly Sensitive Quantitative Detector of Low Antibody LevelsJournal of Interferon & Cytokine Research, 2009
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseThe New England Journal of Medicine, 2008
- Association of an IRF5 gene functional polymorphism with Sjögren's syndromeArthritis & Rheumatism, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006